Important Safety Information | NIOX VERO® User Manual (PDF)
For Healthcare Professionals OnlyDistributors
Take a scroll through our deep routed passion for improving asthma diagnosis and management.
NIOX® wins Leaders in FeNO Testing Technology Development at the AI Research & Development Awards 2022.
The company changes its name to reflect its dedication to point-of-care asthma diagnosis and management with NIOX®, the device of choice for FeNO testing.1
NIOX® is awarded Best FeNO Testing Provider at the M&A Today Global Awards 2022.
NIOX VERO® is named Most Innovative Asthma Management Technology 2021 at the Global Health and Pharma Awards.
NIOX VERO® wins for Circassia as the company takes home Global Leaders in FeNO Testing 2021 at the Global Health and Pharma Awards.
Over 40 million FeNO tests have been performed with NIOX® technology, a major milestone.
NIOX VERO® wins MedTech Award for the Most Advanced Asthma Solution 2020
NIOX VERO® maker Circassia wins Small Diagnostic Manufacturer of the Year 2019 from the Association for Respiratory Technology and Physiology (ARTP).
For the first time, GINA recognises the importance of FeNO testing to help assess the Type 2 phenotype and select the right biologic in severe asthma patients.
NIOX VERO® introduces the nasal application for the measurement of nNO, bringing new options for the diagnosis of primary ciliary dyskinesia (PCD).
NIOX VERO® comes to market, introducing the breathing handle for the most convenient FeNO testing experience.
The ATS issues guidelines on interpreting FeNO levels derived from clinical studies in which 83% of participants tested with NIOX® technology.
The European Respiratory Society (ERS) and the American Thoracic Society (ATS) publish a joint recommendation on the standardisation of FeNO and nasal NO (nNO) measurement techniques.
The introduction of NIOX MINO® offers users a hand-held, portable FeNO analyser for the first time.
NIOX FLEX® is cleared by the US Food and Drug Administration for monitoring asthma.
NIOX FLEX® receives approval as a medical device in Europe, enhancing testing capabilities for healthcare professionals in the diagnosis and management of asthma.
The first FeNO device for commercial use is created at the Karolinska Institute.
The Nobel Prize in Physiology or Medicine was awarded for discoveries concerning NO as a signalling molecule.
A reduction in NO after steroid therapy in asthma patients is uncovered for the first time.
Scientists demonstrate that asthma patients exhale increased levels of NO.
Science magazine names NO its Molecule of the Year, citing the versatility and importance of the gas.
Researchers at the Karolinska Institute in Sweden identified the presence of NO in human lungs.
The importance of nitric oxide was established in the late 1980s when scientists discovered this tiny molecule had signalling properties. Their work would eventually lead to a Nobel Prize.
Join the thousands of healthcare professionals who have already performed over 45 million FeNO tests with NIOX®, and improve patient outcomes.
Join the thousands of healthcare professionals testing FeNO with NIOX®
Get in touch with the NIOX® team to arrange a virtual or live demonstration of NIOX VERO®
Contact Customer Service to make a general enquiry about NIOX VERO®
1. NIOX®. Data on File; MKT-DOF-006. March 2023.